Last reviewed · How we verify

Vitamin D: liquid form, start monthly

University Hospital, Basel, Switzerland · FDA-approved active Small molecule

Vitamin D acts as a steroid hormone that binds to vitamin D receptors to regulate calcium and phosphate homeostasis, immune function, and cell differentiation.

Vitamin D acts as a steroid hormone that binds to vitamin D receptors to regulate calcium and phosphate homeostasis, immune function, and cell differentiation. Used for Vitamin D deficiency supplementation, Hypocalcemia management, Osteoporosis prevention and treatment.

At a glance

Generic nameVitamin D: liquid form, start monthly
Also known asVi-De 3 Monatsdosis
SponsorUniversity Hospital, Basel, Switzerland
Drug classVitamin/steroid hormone
TargetVitamin D receptor (VDR)
ModalitySmall molecule
Therapeutic areaEndocrinology/Bone metabolism/Immunology
PhaseFDA-approved

Mechanism of action

Vitamin D (cholecalciferol or ergocalciferol) is converted in the liver and kidneys to its active form, calcitriol (1,25-dihydroxyvitamin D3), which binds to the vitamin D receptor (VDR) in target tissues. This activates gene transcription involved in calcium absorption in the intestine, bone mineralization, immune regulation, and cellular proliferation and differentiation. The monthly liquid formulation provides convenient dosing for vitamin D supplementation or replacement therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: